Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
Abstract Based on our previous phase II clinical trial of anti-programmed death-1 (PD-1) antibody nivolumab for platinum-resistant ovarian cancer (n = 19, UMIN000005714), we aimed to identify the biomarkers predictive of response. Tumor gene expression was evaluated by proliferative, mesenchymal, di...
Guardado en:
Autores principales: | Ryusuke Murakami, Junzo Hamanishi, J. B. Brown, Kaoru Abiko, Koji Yamanoi, Mana Taki, Yuko Hosoe, Ken Yamaguchi, Tsukasa Baba, Noriomi Matsumura, Ikuo Konishi, Masaki Mandai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2172fc8b2d534ff6b34b0f655aab8608 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
por: Koji Yamanoi, et al.
Publicado: (2019) -
Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation
por: Mana Taki, et al.
Publicado: (2018) -
Figla promotes secondary follicle growth in mature mice
por: Asuka Okunomiya, et al.
Publicado: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021) -
Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021)